AHA Scientific Sessions 2025 Abstract
Immunogenicity of Recaticimab Does Not Impact Its Efficacy in Patients with Dyslipidemia: A Pooled Analysis of Three Phase III and One Phase Ib/II Studies
Trial in peopleInterventions
The paper
Shanghai Jiao Tong University
AHA Scientific Sessions 2025 Abstract, 3 Nov 2025
Presented at AHA Scientific Sessions 2025, abstract 4368112
